The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Pa
- PDF / 1,163,838 Bytes
- 17 Pages / 595.276 x 790.866 pts Page_size
- 69 Downloads / 194 Views
ORIGINAL RESEARCH
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Baseline Patient-Reported Outcomes Kristina S. Boye . He´le`ne Sapin . Luis-Emilio Garcı´a-Pe´rez . Myriam Rosilio . Marco Orsini Federici . Elke Heitmann . Heike Jung . Ulrich Aigner . Bruno Guerci . Francesco Giorgino . Kirsi Norrbacka Received: June 5, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: Although patient-reported outcome (PRO) measures provide important information beyond clinical data, studies that assess the PROs of type 2 diabetes mellitus (T2DM) patients initiating injectable glucose-lowering medications in routine clinical practice are limited. We describe the perspectives of patients based on a diversified panel of generic and
Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12783287. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s13300020-00908-9) contains supplementary material, which is available to authorized users. K. S. Boye (&) Eli Lilly and Company, Indianapolis, IN, USA e-mail: [email protected]
disease-specific PRO measures at the time of enrollment (baseline) in the TROPHIES study. Methods: TROPHIES is a 24-month prospective observational study performed in France, Germany, and Italy in patients with T2DM who initiated their first injectable glucose-lowering medication with once-weekly dulaglutide or once-daily liraglutide. To better understand the perspectives of these patients regarding their overall health, treatment satisfaction, and quality of life and work, the patients’ responses to the following questionnaires were collected at baseline before they initiated treatment with dulaglutide or liraglutide: EQ-5D-5L (scale: 0–1), EQ-VAS (visual analog scale: 0–100), Impact of Weight on Self-Perceptions Questionnaire (IWSP; scale: 0–100), Diabetes Treatment Satisfaction Questionnaire Status (DTSQs; scale: 0–36),
U. Aigner Versdias GmbH, Sulzbach-Rosenberg, Germany
H. Sapin M. Rosilio Lilly France SAS, Neuilly-sur-Seine, France
B. Guerci University Hospital of Nancy, Vandoeuvre Le`s Nancy, France
L.-E. Garcı´a-Pe´rez Lilly S.A., Alcobendas, Madrid, Spain
F. Giorgino University of Bari Aldo Moro, Bari, Italy
M. Orsini Federici Eli Lilly and Company, Sesto Fiorentino, FI, Italy
K. Norrbacka Eli Lilly and Company, Helsinki, Finland
E. Heitmann H. Jung Lilly Deutschland GmbH, Bad Homburg, Germany
Diabetes Ther
and Diabetes Productivity Measure (DPM; scale: 0–100). Analyses were descriptive in nature, with higher scores reflecting better outcomes. Results: Data from patients at the time of enrollment were analyzed. At baseline, patients initiating dulaglutide (N = 1130) or liraglutide (N = 1051) rated their quality of life in terms of mean EQ-5D-5L index as 0.84 and 0.83, and in terms of mean EQ-VAS as 67.5 and 67.5, respectively. The mean baseline scores in patients initiating dulaglutide or liraglutide
Data Loading...
